Aligning Connecticut’s bioscience interests with government policy.

Advocacy is a critical component of our community outreach.

Government Affairs Committee

Our mission is to provide education and advocacy for Connecticut’s bioscience and life science communities at the policy level and ensure synergy of action and alignment of state and federal initiatives that have a significant impact on our members.

The Government Affairs Committee is comprised of BioCT board members, industry executives and business advisors including the government relations firm of Rome, Smith & Lutz, which has deep expertise in matters impacting our industry.

Dawn Hocevar
President & CEO,
BioCT

Todd Arnold, Ph.D.
Chief Laboratory Operations Officer,
Sema4
BioCT Director

Joni Arvai
Senior Manager, State Government Affairs,
Bristol-Myers Squibb

Kathy Andrews Bilotas
Director of State Government Affairs,
Eli Lilly

Bill Claffey, J.D.
Partner, Tax Services,
Fiondella, Milone & LaSaracina

Jennifer Deperry
Alliance Development Manager,
Pfizer

Jennifer Herz
State Government Affairs, Regional Director,
Boeringer Ingelheim

Ken Hiscoe
Director, US Government Relations/Corporate Affairs,
Pfizer

Richard Jacob
Associate Vice President for Federal Relations,
Yale University
BioCT
 Director

Delman Lebel
Director, State Government Affairs and Public Policy,
Regeneron Pharmaceuticals

Katherine Lutz
Partner,
Rome, Smith & Lutz

Joseph Oros
Regional Director, State Government Affairs,
AbbVie

Jack Quinn
Head of State Government Affairs,
Alexion

Lonnie Reed
Former State Representative

Lisa Roy
Director of Government & Community Relations,
Jackson Laboratory

Dmitri Siegel
Director, Alliance Development
Bristol-Myers Squibb

Kelly Sinko Steuber
Director, Governmental Relations for Health Affairs,
University of Connecticut

Christopher Smith
Vice President,
Rome Smith & Lutz

Karla White
State Government Affairs Manager, East Coast,
CSL Behring

i am bioct

“BioCT advocates as the voice of the bioscience community. Our goal is to make sure that the legislators understand: who we are, what we do, what we need to be successful, and how critical our industry is to the development of the next therapy and innovation in patient care.”

Dawn Hocevar
President & CEO
BioCT